NCT00540085

Pharmacodynamic Trial on Rocuronium in Obese Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Rigshospitalet, Denmark · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Aim: To optimize the use of rocuronium (a neuromuscular blocking agent) in obese patients undergoing gastric bypass or gastric banding. Background: During general anaesthesia, a neuromuscular blocking agent is needed to allow surgery and airway management. Optimal dosing is important in order to avoid inadequately muscle relaxation, but also to avoid overdosage, which can result in prolonged anaesthesia and respiratory complications. Main hypothesis: Rocuronium dosed according to ideal body weight results in shorter duration of action compared to rocuronium dosed according to corrected body weight without prolonged onset time or compromised airway management or surgical demands for muscle relaxation.

Conditions

• Bariatric Surgery

Interventions

Type	Name	Description
DRUG	Rocuronium	0.6 mg/kg given intravenously before intubation

Timeline

• Start date: 2007-10-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2007-10-05
• Last updated: 2009-10-16

Locations

1 site across 1 country: Denmark